EUVIMEDEUVIMED entdecken
Crossref

COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1669e ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2Antibodies, MonoclonalDrug CombinationsAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19Evusheldcilgavimabefficacytixagevimab

Substanzen

cilgavimab and tixagevimab drug combinationAntibodies, MonoclonalDrug CombinationsAntibodies, Neutralizing

Zitieren

APA

(2023). COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669e

Vancouver

COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669e

BibTeX
@article{euvimed2023,
  title = {COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1669e}
}
Kostenlos starten →